Transcriptomics

Dataset Information

3

Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib


ABSTRACT: Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant cells vs. WT cells responding to erlotinib. 4 EGFR mutant and 4 WT NSCLC cells were treated with or without erlotinib for 24 hr, followed by RNA extraction and hybridization on Affymetrix microarrays.

ORGANISM(S): Homo sapiens  

SUBMITTER: Ho-June Lee   Pan Du 

PROVIDER: E-GEOD-57156 | ArrayExpress | 2014-05-16

SECONDARY ACCESSION(S): GSE57156PRJNA245807

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2014-12-03 | E-GEOD-63784 | ArrayExpress
2013-08-10 | E-GEOD-49135 | ArrayExpress
2014-10-07 | E-GEOD-62118 | ArrayExpress
2019-11-14 | PXD014198 | Pride
2014-04-08 | E-GEOD-45891 | ArrayExpress
| GSE62061 | GEO
2012-05-29 | E-GEOD-38310 | ArrayExpress
| GSE95558 | GEO
| GSE95590 | GEO
2018-10-18 | PXD005985 | Pride